Oral corticosteroid sparing effects of anti-IL5/ anti-IL5 receptor treatment after 2 years of treatment
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oral corticosteroid sparing effects of anti-IL5/ anti-IL5 receptor treatment after 2 years of treatment
Authors
Keywords
Severe asthma, Biologicals, Real-life study, Oral corticosteroids
Journal
RESPIRATORY MEDICINE
Volume 176, Issue -, Pages 106260
Publisher
Elsevier BV
Online
2020-11-27
DOI
10.1016/j.rmed.2020.106260
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-life experience with benralizumab during 6 months
- (2020) A. Padilla-Galo et al. BMC Pulmonary Medicine
- Management of Severe Asthma: a European Respiratory Society/American Thoracic Society Guideline
- (2019) Fernando Holguin et al. EUROPEAN RESPIRATORY JOURNAL
- Real-life studies of biologics used in asthma patients: key differences and similarities to trials
- (2019) Enrico Heffler et al. Expert Review of Clinical Immunology
- Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma
- (2019) Barak Pertzov et al. JOURNAL OF ASTHMA
- One year of mepolizumab. Efficacy and safety in real-life in Italy
- (2019) Diego Bagnasco et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response
- (2019) Marco Caminati et al. Expert Review of Respiratory Medicine
- Oral corticosteroid exposure and adverse effects in asthmatic patients
- (2018) Patrick W. Sullivan et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study
- (2018) Corrado Pelaia et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials
- (2018) Diego Bagnasco et al. World Allergy Organization Journal
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
- (2017) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
- (2016) Eugene R Bleecker et al. LANCET
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
- (2016) J Mark FitzGerald et al. LANCET
- Acute and chronic systemic corticosteroid–related complications in patients with severe asthma
- (2015) Patrick Lefebvre et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
- (2015) Mario Castro et al. Lancet Respiratory Medicine
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
- (2014) Elisabeth H. Bel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
- (2014) Hector G. Ortega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
- (2012) Ian D Pavord et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now